Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers.
Başcı S, Ata N, Altuntaş F, Yiğenoğlu TN, Dal MS, Korkmaz S, Namdaroğlu S, Baştürk A, Hacıbekiroğlu T, Doğu MH, Berber İ, Dal K, Erkurt MA, Turgut B, Çelik O, Ülgü MM, Birinci Ş; Turkish Ministry of Health, Hematology Scientific Working Group. Başcı S, et al. Intern Emerg Med. 2022 Jan;17(1):135-139. doi: 10.1007/s11739-021-02784-y. Epub 2021 Jun 10. Intern Emerg Med. 2022. PMID: 34110562 Free PMC article.
The effect of high-dose cytarabine followed by autologous hematopoietic stem cell transplantation on the outcome of patients with mantle cell lymphoma.
Çakar MK, Tekgündüz E, Dal MS, Merdin A, Başçı S, İskender D, Uğur B, Bekdemir F, Yıldız J, Ulu BU, Bakırtaş M, Yiğenoğlu TN, Batgi H, Kaya AH, İskender D, Altuntaş F. Çakar MK, et al. Among authors: basci s. J Oncol Pharm Pract. 2020 Mar;26(2):273-278. doi: 10.1177/1078155219841110. Epub 2019 Apr 2. J Oncol Pharm Pract. 2020. PMID: 30940050
Evaluation of neutropenia-related outcomes in Hodgkin's lymphoma patients with moderate or severe neutropenia who received ABVD chemotherapy without using granulocyte-colony stimulating factor.
Merdin A, Çakar MK, Dal MS, Mert D, Yıldız J, Başçı S, Bakırtaş M, Darçın T, Şahin D, Ulu BU, Yiğenoğlu TN, Batgi H, Tetik A, İskender D, Altuntaş F. Merdin A, et al. Among authors: basci s. J Oncol Pharm Pract. 2020 Jun;26(4):929-932. doi: 10.1177/1078155219891663. Epub 2019 Dec 10. J Oncol Pharm Pract. 2020. PMID: 31822199
The effect of serum vitamin B12, folate, ferritin levels and transferrin saturation on stem cell mobilization in allogeneic donors.
Yiğenoğlu TN, Başcı S, Bakırtaş M, Ulu BU, Kılınç A, Şahin D, Darçın T, Yıldız J, Merdin A, Baysal NA, İskender D, Çakar MK, Dal MS, Hacıbekiroğlu T, Altuntaş F. Yiğenoğlu TN, et al. Among authors: basci s. Transfus Apher Sci. 2020 Jun;59(3):102726. doi: 10.1016/j.transci.2020.102726. Epub 2020 Jan 9. Transfus Apher Sci. 2020. PMID: 32008954
Inferior prognosis in poor mobilizing myeloma patients.
Yiğenoğlu TN, Başcı S, Ulu BU, Bakırtaş M, Kılınç A, Şahin D, Darçın T, Yıldız J, Baysal NA, İskender D, Çakar MK, Dal MS, Hacıbekiroğlu T, Altuntaş F. Yiğenoğlu TN, et al. Among authors: basci s. Transfus Apher Sci. 2020 Jun;59(3):102722. doi: 10.1016/j.transci.2020.102722. Epub 2020 Jan 9. Transfus Apher Sci. 2020. PMID: 32014363
The effect of gemcitabine, dexamethasone, and cisplatin chemotherapy in relapsed/refractory NHL and HL patients: A single center experience.
Batgi H, Merdin A, Dal MS, Kızıl Çakar M, Yıldız J, Başçı S, Uncu Ulu B, Yiğenoğlu TN, Darçın T, Şahin D, Bakırtaş M, Tetik A, İskender D, Altuntaş F. Batgi H, et al. Among authors: basci s. J Oncol Pharm Pract. 2020 Dec;26(8):1857-1863. doi: 10.1177/1078155220905654. Epub 2020 Feb 25. J Oncol Pharm Pract. 2020. PMID: 32098553
Analysis of pre-chemotherapy WBC, PLT, monocyte, hemoglobin, and MPV levels in acute myeloid leukemia patients with WT1, FLT3, or NPM gene mutations.
Merdin A, Dal MS, Çakar MK, Yildiz J, Ulu BU, Batgi H, Tetik A, Seçilmiş S, Darçin T, Şahin D, Bakirtaş M, Başçi S, Yiğenoğlu TN, Baysal NA, İskender D, Altuntaş F. Merdin A, et al. Among authors: basci s. Medicine (Baltimore). 2020 Apr;99(14):e19627. doi: 10.1097/MD.0000000000019627. Medicine (Baltimore). 2020. PMID: 32243389 Free PMC article.
The outcome of COVID-19 in patients with hematological malignancy.
Yigenoglu TN, Ata N, Altuntas F, Bascı S, Dal MS, Korkmaz S, Namdaroglu S, Basturk A, Hacıbekiroglu T, Dogu MH, Berber İ, Dal K, Erkurt MA, Turgut B, Ulgu MM, Celik O, Imrat E, Birinci S. Yigenoglu TN, et al. Among authors: basci s. J Med Virol. 2021 Feb;93(2):1099-1104. doi: 10.1002/jmv.26404. Epub 2020 Aug 26. J Med Virol. 2021. PMID: 32776581 Free PMC article.
Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors.
Başcı S, Ata N, Altuntaş F, Yiğenoğlu TN, Dal MS, Korkmaz S, Namdaroğlu S, Baştürk A, Hacıbekiroğlu T, Doğu MH, Berber İ, Dal K, Erkurt MA, Turgut B, Çağlayan M, Ayvalı MO, Çelik O, Ülgü MM, Birinci Ş; Turkish Ministry of Health, Hematology Scientific Working Group. Başcı S, et al. J Oncol Pharm Pract. 2020 Oct;26(7):1676-1682. doi: 10.1177/1078155220953198. Epub 2020 Aug 27. J Oncol Pharm Pract. 2020. PMID: 32854573 Free PMC article.
Convalescent plasma therapy in patients with COVID-19.
Altuntas F, Ata N, Yigenoglu TN, Bascı S, Dal MS, Korkmaz S, Namdaroglu S, Basturk A, Hacıbekiroglu T, Dogu MH, Berber İ, Dal K, Kınık K, Haznedaroglu İ, Yılmaz FM, Kılıç İ, Demircioğlu S, Yosunkaya A, Erkurt MA, Turgut B, Caglayan M, Celik O. Altuntas F, et al. Among authors: basci s. Transfus Apher Sci. 2021 Feb;60(1):102955. doi: 10.1016/j.transci.2020.102955. Epub 2020 Sep 19. Transfus Apher Sci. 2021. PMID: 33011076 Free PMC article.
37 results